Suven Life Sciences Limited has informed the Exchange regarding a press release dated Jun 01, 2023, titled "Suven Life Sciences completed enrollment of patients to the phase-2, Proof of Concept (PoC) clinical study of samelisant (SUVN-G3031) for the treatment of narcolepsy with or without cataplexy in USA and Canada".